Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia? - Wikidata - wikimedia - TriplyDB

Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?

Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?

http://www.wikidata.org/entity/Q35202588

about

Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?

http://www.wikidata.org/entity/Q35202588

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Evidence-based mini-review: Sh ...... to acute myelogenous leukemia?

@ast

Evidence-based mini-review: Sh ...... to acute myelogenous leukemia?

@en

type

label

Evidence-based mini-review: Sh ...... to acute myelogenous leukemia?

@ast

Evidence-based mini-review: Sh ...... to acute myelogenous leukemia?

@en

prefLabel

Evidence-based mini-review: Sh ...... to acute myelogenous leukemia?

@ast

Evidence-based mini-review: Sh ...... to acute myelogenous leukemia?

@en

P1433

Q35202588-32749358-4F0B-4D04-B7BB-6753A2333BC3

P1476

Q35202588-E7740629-BC02-403E-B104-28C383B71FF6

P2093

Q35202588-4EE80431-7291-47F8-8AF7-DA38B42DF0CD

Q35202588-7F77A952-C9FA-44FC-B15E-9E02F207B1DB

P2860

Q35202588-019B8304-5033-4797-83B2-574A04B393B1

Q35202588-24C0DC9F-9975-4D96-B341-051FE64E73C0

Q35202588-485FF568-EA2F-4FD6-9502-859AAECBBBD0

Q35202588-4D0068FF-AF66-454A-9B83-7DCC2FF11627

Q35202588-4F5BACBB-B7E0-4D12-AA2F-16E48FBD2973

Q35202588-52BE79B3-DA6A-48F3-959C-F4812C351D84

Q35202588-5FB9A3EA-69CE-4682-868B-F05CE9C3FC5B

Q35202588-64194A1C-1921-44F3-8CAB-E65E6D92208C

Q35202588-909654E9-AD3C-4381-B95D-C743BF9BA9EC

Q35202588-B131AEC8-60AD-4A29-BF21-497942CD83AC

P304

Q35202588-427610A4-E4D0-40D6-9015-326FC8B35FCC

P31

Q35202588-DC9AB6C1-1784-4FB6-8319-CC4D16B25071

P356

Q35202588-D446E606-466C-426E-B19C-A8E74A746512

P478

Q35202588-D7A35103-3B19-48F6-909C-C5690E4C3699

P577

Q35202588-0B3DF536-B7D9-446C-B71A-C6B2AAE1A14B

P5875

Q35202588-856D8A3B-6A9D-41B8-88AF-88B518484862

P698

Q35202588-DF0853FE-8E24-4FA3-A83F-F8ACA02CD0DC

P932

Q35202588-A0FAF781-A999-4CF0-BACA-A8AE50A0EEC3

P356

ASHEDUCATION-2010.1.322

P1433

Hematology / the Education Program of the American Society of Hematology

P1476

Evidence-based mini-review: Sh ...... to acute myelogenous leukemia?

@en

P2093

Mark A Schroeder

http://www.w3.org/2001/XMLSchema#string

William Blum

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.

Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

P304

322-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/ASHEDUCATION-2010.1.322

http://www.w3.org/2001/XMLSchema#string

P478

2010

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49760146

http://www.w3.org/2001/XMLSchema#string

P698

21239813

http://www.w3.org/2001/XMLSchema#string

P932

3169102

http://www.w3.org/2001/XMLSchema#string